The practiced modesty may be new—and not his native style—but the substance is old-school Baldino. Although predictions in pharma are folly, with Cephalon stock and strategy stronger than ever, no one should be surprised to see its boss still playing at the big table—placing bets and winning—in another 20 years.

This online version incorporates corrections made in the printed version.